Neurocrine Biosciences, Inc. — Drug Manufacturers - Specialty & Generic. Scored on the same transparent 7-signal model behind the daily rankings.
★
NBIX
Neurocrine Biosciences, Inc. · Drug Manufacturers - Specialty & Generic
FCF$831mC+
Rev+21.4%A-
D/E0.14B+
P/E27.8xB
PEG0.49A
87Score
$180.55$18.2B
1Y Target$197.95Analyst consensus · 27 analysts
5Y Target$249.91Compound horizon
10Y Target$320.50Long-dated conviction
FCF$831mTTMC+
FCF $831m — respectable but not differentiating
Rev+21.4%TTM YoYA-
Revenue +21.4% — strong growth, well above S&P median (~7%)
D/E0.14B+
D/E 0.14 — below the Healthcare debt median (≈40th pctile)
P/E27.8xB
P/E 27.8 — near the Healthcare median (≈60th pctile)
PEG0.49A
PEG 0.49 — exceptional; paying well under fair value for growth
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 87
Quality0.83
Growth1.00
Value0.80
Why this score
Durable high returns
Entry · Margin of safety
52-week rangeNear 52-week high
0% off the 12-month high
vs DCF fair value3% belowest. fair value ~$186
Quality signals · context only
Gross profitability62% · Agross profit ÷ total assets (Novy-Marx)
ROIC18.3% · A-return on invested capital — not score-weighted
Why now
Neurocrine Biosciences is a compelling growth story, demonstrating robust expansion driven by its specialized pharmaceutical portfolio, particularly INGREZZA for tardive dyskinesia and Huntington's chorea. With revenue growth at 21.4% (FY YoY) and a strong profit margin of 21.6%, the company efficiently converts sales into earnings. The exceptionally low PEG ratio of 0.49 signals that its significant growth is undervalued relative to its current P/E of 27.8, making it a 'strong_buy' consensus among analysts, with the crux resting on continued pipeline success and market penetration of its existing specialized drugs.
Moat
Neurocrine's durable edge stems from its deep intellectual property and specialized R&D capabilities in neurological, psychiatric, endocrine, and immunological disorders, creating high barriers to entry. Products like INGREZZA, Orilissa, and CRENESSITY address specific, often underserved, medical conditions, benefiting from regulatory protection and the high cost and time associated with developing competing therapies. This focus on specialty pharmaceuticals, backed by a robust clinical development pipeline including NBI-1076986 and Osavampator, protects its nearly 20% ROE by ensuring pricing power and market exclusivity in its niche segments.
Risk
The primary bear case for Neurocrine Biosciences revolves around pipeline execution and potential competitive threats to its key revenue drivers. Despite a low debt-to-equity of 0.14, the company's valuation, with a P/S TTM of 5.9 and P/E TTM of 27.8, could be vulnerable if clinical trial failures for candidates like NBI-1076986 or Osavampator occur, or if new competitors emerge in the tardive dyskinesia or Huntington's disease markets. The concrete signal confirming the bear case would be a significant setback in a late-stage clinical trial or a material deceleration in INGREZZA's sales growth due to unexpected market erosion.
Horizon
1-3 yr $197.95 (27-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $249.91 at ~7% CAGR — dividend + buyback compounding. 10 yr $320.50 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · NBIX
$
%
%
Shares to buy
11
Position size
$1,986
4.0% of portfolio
Stop price
$135.41
25% below $180.55
$ at risk if stopped
$496.51
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Neurocrine Biosciences, Inc. (NBIX): score, valuation & FAQ
Neurocrine Biosciences, Inc. (NBIX) is a Drug Manufacturers - Specialty & Generic company that scores 87 out of 100 on the Bull Rankings quality-growth model — a strong reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are PEG (A), Rev (A-) and D/E (B+). On valuation, NBIX sits about 3% below our discounted-cash-flow fair value (a margin of safety).
Is NBIX a good stock to buy?
Bull Rankings scores NBIX 87 out of 100 on its quality-growth model, which is a strong reading. That is driven by PEG (A), Rev (A-) and D/E (B+). A score is a quantitative screen of Neurocrine Biosciences, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does NBIX score 87 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). NBIX earns its highest marks on PEG (A), Rev (A-) and D/E (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is NBIX overvalued or undervalued?
Based on $180.55, NBIX sits about 3% below our discounted-cash-flow fair value (a margin of safety). It trades at a 27.8x× P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in NBIX?
The primary bear case for Neurocrine Biosciences revolves around pipeline execution and potential competitive threats to its key revenue drivers. Despite a low debt-to-equity of 0.14, the company's valuation, with a P/S TTM of 5.9 and P/E TTM of 27.8, could be vulnerable if clinical trial failures for candidates like NBI-1076986 or Osavampator occur, or if new competitors emerge in the tardive dyskinesia or Huntington's disease markets. The concrete signal confirming the bear case would be a significant setback in a late-stage clinical trial or a material deceleration in INGREZZA's sales growth due to unexpected market erosion.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.